CA2487425A1 - Combination chemotherapy with chlorotoxin - Google Patents

Combination chemotherapy with chlorotoxin Download PDF

Info

Publication number
CA2487425A1
CA2487425A1 CA002487425A CA2487425A CA2487425A1 CA 2487425 A1 CA2487425 A1 CA 2487425A1 CA 002487425 A CA002487425 A CA 002487425A CA 2487425 A CA2487425 A CA 2487425A CA 2487425 A1 CA2487425 A1 CA 2487425A1
Authority
CA
Canada
Prior art keywords
cancer
chlorotoxin
xaa
cys
carcinoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002487425A
Other languages
English (en)
French (fr)
Inventor
Vernon L. Alvarez
Carol A. Grimes
Matthew A. Gonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transmolecular Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2487425A1 publication Critical patent/CA2487425A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43522—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from scorpions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Insects & Arthropods (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
CA002487425A 2002-05-31 2003-06-02 Combination chemotherapy with chlorotoxin Abandoned CA2487425A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38417102P 2002-05-31 2002-05-31
US60/384,171 2002-05-31
US40603302P 2002-08-27 2002-08-27
US60/406,033 2002-08-27
PCT/US2003/017410 WO2003101474A1 (en) 2002-05-31 2003-06-02 Combination chemotherapy with chlorotoxin

Publications (1)

Publication Number Publication Date
CA2487425A1 true CA2487425A1 (en) 2003-12-11

Family

ID=29715313

Family Applications (2)

Application Number Title Priority Date Filing Date
CA002487425A Abandoned CA2487425A1 (en) 2002-05-31 2003-06-02 Combination chemotherapy with chlorotoxin
CA002494451A Abandoned CA2494451A1 (en) 2002-05-31 2003-06-02 Treatment of cell proliferative disorders with chlorotoxin

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA002494451A Abandoned CA2494451A1 (en) 2002-05-31 2003-06-02 Treatment of cell proliferative disorders with chlorotoxin

Country Status (10)

Country Link
US (1) US20060166892A1 (cg-RX-API-DMAC7.html)
EP (4) EP1553962B1 (cg-RX-API-DMAC7.html)
JP (3) JP2005537234A (cg-RX-API-DMAC7.html)
AT (1) ATE458751T1 (cg-RX-API-DMAC7.html)
AU (2) AU2003237347B2 (cg-RX-API-DMAC7.html)
CA (2) CA2487425A1 (cg-RX-API-DMAC7.html)
DE (1) DE60331458D1 (cg-RX-API-DMAC7.html)
ES (1) ES2341767T3 (cg-RX-API-DMAC7.html)
MX (1) MXPA04011871A (cg-RX-API-DMAC7.html)
WO (2) WO2003101475A1 (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060088899A1 (en) * 2002-05-31 2006-04-27 Alvarez Vernon L Combination chemotherapy with chlorotoxin
US20070275902A1 (en) * 2003-11-26 2007-11-29 Transmolecular, Inc. Treatment of Phosphatidylinositol Phospholipid Disorders
ATE459642T1 (de) * 2004-04-06 2010-03-15 Transmolecular Inc Diagnose und behandlung von myeloid- und lymphoidzellenkrebs mit chlorotoxin oder derivat
EP1877428B1 (en) * 2005-04-22 2011-03-16 University of Washington Cyanine- chlorotoxin conjugate and method for intra-operative visualization of cancer
CA2647907A1 (en) * 2006-03-31 2007-10-18 Transmolecular, Inc. Use of tm-601 for the diagnosis and treatment of tumors
US8106013B2 (en) 2006-05-19 2012-01-31 Georgia Tech Research Corporation ABC transporter ligand GATX1
CN100590130C (zh) * 2007-07-31 2010-02-17 厦门北大之路生物工程有限公司 抗癌活性肽
EP2173385A1 (en) * 2007-08-07 2010-04-14 Transmolecular, Inc. Chlorotoxins as drug carriers
CA2702314A1 (en) * 2007-10-12 2009-04-16 Transmolecular, Inc. Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
CN102438646A (zh) * 2008-05-15 2012-05-02 特兰斯莫莱库拉公司 转移性肿瘤的治疗
CA2724384A1 (en) 2008-05-15 2009-11-19 Transmolecular, Inc. Treatment of metastatic tumors
WO2010086964A1 (ja) * 2009-01-28 2010-08-05 株式会社 静岡カフェイン工業所 がん治療のための併用療法
JP5858932B2 (ja) * 2010-02-04 2016-02-10 モルフォテック, インコーポレイテッド クロロトキシンポリペプチドおよびコンジュゲートならびにその使用
ES2601182T3 (es) * 2010-05-11 2017-02-14 Fred Hutchinson Cancer Research Center Variantes de clorotoxina, conjugados y métodos para su utilización
CU24055B1 (es) * 2010-09-27 2014-12-26 Grupo Empresarial De Producciones Biofarmacéuticas Y Químicas Labiofam Composiciones farmacéuticas de veneno de escorpión rhopalurus junceus
GB201106004D0 (en) 2011-04-08 2011-05-25 Univ Edinburgh Optical imaging probes
WO2013003507A1 (en) 2011-06-27 2013-01-03 Morphotek, Inc. Multifunctional agents
WO2013158803A1 (en) 2012-04-17 2013-10-24 Merrimack Pharmaceuticals, Inc. Compositions and methods for non-invasive imaging
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
US9717724B2 (en) 2012-06-13 2017-08-01 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies
SG11201504600UA (en) 2012-12-10 2015-07-30 Hutchinson Fred Cancer Res Methods for screening
JP2016523818A (ja) * 2013-04-18 2016-08-12 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル それを必要とする被験体におけるt細胞増殖を阻害するための方法及び医薬組成物(ctps1阻害剤、例えばノルロイシン)
US11559580B1 (en) 2013-09-17 2023-01-24 Blaze Bioscience, Inc. Tissue-homing peptide conjugates and methods of use thereof
WO2015061592A1 (en) * 2013-10-23 2015-04-30 Merrimack Pharmaceuticals, Inc. Liposomes for non-invasive imaging and drug delivery
US9522114B1 (en) * 2014-03-27 2016-12-20 University Of South Florida Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin
US11318131B2 (en) 2015-05-18 2022-05-03 Ipsen Biopharm Ltd. Nanoliposomal irinotecan for use in treating small cell lung cancer
SG10201913073YA (en) 2015-08-20 2020-03-30 Ipsen Biopharm Ltd Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment
EP3791876A1 (en) 2015-08-21 2021-03-17 Ipsen Biopharm Ltd. Methods for treating metastatic pancreatic cancer using combination therapies comprising liposomal irinotecan and oxaliplatin
CA3053242A1 (en) * 2016-02-19 2017-08-24 Dignity Health Antibody fusion protein and related compositions for targeting cancer
US12048732B2 (en) 2016-04-15 2024-07-30 Blaze Bioscience, Inc. Methods of treating breast cancer
KR101678393B1 (ko) 2016-08-25 2016-12-06 (주)넥스젠바이오텍 피부 세포 증식 효과가 증가한 전갈독 융합단백질 및 이를 유효성분으로 함유하는 피부 주름 개선, 피부 탄력 증대 및 항노화 화장료 조성물
RU2761953C2 (ru) 2016-11-02 2021-12-14 Ипсен Биофарм Лтд. Лечение рака желудка с применением комбинационных видов терапии, содержащих липосомальный иринотекан, оксалиплатин, 5-фторурацил (и лейковорин)
WO2019055840A1 (en) 2017-09-15 2019-03-21 Eisai Inc. CHLOROTOXIN AGENTS AND USES THEREOF
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69025946T2 (de) * 1989-09-08 1996-10-17 Univ Duke Modifikationen der struktur des egf-rezeptor-gens in menschlichen glioma
US5223253A (en) * 1989-09-28 1993-06-29 American Home Products Corporation Bovine vaccine compositions and method for preventing trichomonas infections using same
US5750376A (en) * 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
IL108328A (en) * 1993-01-14 2010-05-31 Cancer Res Campaign Tech Pharmaceutical compositions containing temozolomide and atase inhibitor for potentiation of temozolomide toxicity to human tumor cells
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5756340A (en) * 1995-05-08 1998-05-26 The Regents Of The University Of California Insect control with multiple toxins
JP3809502B2 (ja) * 1995-05-30 2006-08-16 二郎 有川 ハンタウィルス抗原蛋白質およびモノクローナル抗体
JPH0971599A (ja) * 1995-09-06 1997-03-18 Nippon Seibutsu Kagaku Kenkyusho 鶏貧血ウイルス(cav)感染鶏血清と高い反応性を示すポリペプチド及びこのポリペプチドに対する抗体、鶏貧血ウイルス感染の診断法及びワクチン
US5905027A (en) * 1995-12-27 1999-05-18 Uab Research Foundation Method of diagnosing and treating gliomas
US6667156B2 (en) * 1995-12-27 2003-12-23 Uab Research Foundation Diagnosis and treatment of neuroectodermal tumors
EP1055684A4 (en) * 1997-12-05 2002-12-04 Kyogo Itoh TUMORANTIGENS IN THE FORM OF PEPTIDE DERIVATIVES

Also Published As

Publication number Publication date
EP2431385A3 (en) 2012-07-04
DE60331458D1 (de) 2010-04-08
AU2003237347A1 (en) 2003-12-19
EP1539207A1 (en) 2005-06-15
JP2011153149A (ja) 2011-08-11
CA2494451A1 (en) 2003-12-11
US20060166892A1 (en) 2006-07-27
EP2431385A2 (en) 2012-03-21
EP1539207A4 (en) 2008-01-02
EP2182004A1 (en) 2010-05-05
JP5856744B2 (ja) 2016-02-10
JP2015214562A (ja) 2015-12-03
AU2003240496A1 (en) 2003-12-19
AU2003237347B2 (en) 2009-07-23
WO2003101475A1 (en) 2003-12-11
JP2005537234A (ja) 2005-12-08
WO2003101474A1 (en) 2003-12-11
MXPA04011871A (es) 2005-07-26
ATE458751T1 (de) 2010-03-15
ES2341767T3 (es) 2010-06-28
EP1553962A1 (en) 2005-07-20
AU2003240496B2 (en) 2008-01-10
EP1553962B1 (en) 2010-02-24
EP1553962A4 (en) 2008-01-02

Similar Documents

Publication Publication Date Title
AU2003240496B2 (en) Combination chemotherapy with chlorotoxin
US20100210546A1 (en) Combination chemotherapy with chlorotoxin
US20070258893A1 (en) Compositions and methods for imaging expression of cell surface receptors
US20100135905A1 (en) Assessment of cancer susceptibility to molecular targeted therapy by use of recombinant peptides
US8133471B2 (en) CLK-peptide and SLK-peptide
CN107405382A (zh) 用于改善认知的方法和组合物
US20200397894A1 (en) Compositions and methods for treating cancer
CA2647907A1 (en) Use of tm-601 for the diagnosis and treatment of tumors
KR101110758B1 (ko) 뇌졸중 표적용 펩티드 및 이의 용도
DaSilva et al. In vivo imaging of monoaminergic nerve terminals in normal and MPTP‐lesioned primate brain using positron emission tomography (PET) and [11C] tetrabenazine
Schmidt et al. Therapeutic nuclear medicine in pediatric malignancy
AU2012272550B2 (en) Prevention and treatment of acute inflammatory conditions
CA2358427A1 (en) Method for diagnosing, imaging, and treating tumors using restrictive receptor for interleukin 13
Pauwels et al. Molecular imaging of norepinephrine transporter-expressing tumors: current status and future prospects
US20220001039A1 (en) Compositions and methods for detecting ace2 expression profiles
HK1172630A (en) Combination therapy with chlorotoxin
CN113874029B (zh) 基于cp2c靶向肽的抗癌剂
US20170326166A1 (en) Compositions and methods for treating pituitary tumors
Volterrani et al. Hybrid imaging and radionuclide therapy of neuroendocrine tumors
Jiang et al. Combating drug-resistant Staphylococcus aureus infection with pathogen-specific positron emission tomography and targeted radionuclide therapy
Fang et al. Chronic Effects of Cocaine on Dopaminergic and Serotonergic Systems of Rats

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20160708